Replies to post #296 on Fate Therapeutics Inc (FATE)

[jondoeuk]

If they could upend auto BCMA and/or CD19 CARs, I think it might.

As for HER2, that is partnered with Ono Pharma, a CAR-T, with several edits (CAR uses a CD28zeta mutant that contains one instead of all three iTAMs, TCR knockout, high-affinity and non-cleavable CD16 receptor, IL-7 receptor, CD38 knockout, TGF-R 'switch' receptor, and CXCR2 chemokine receptor).